Skip to main content

AS/Spondyloarthritis

Weak Data (1.24.2025)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.

Read Article
Korean Biologics (KOBIO) registry showed SpA pts have higher risk of infection. 2,129 AS pts (7108 PY FU) most common was respiratory infx (26/1000 PY), followed by herpes zoster (6/1000 PY) Risk includes age, ischemic CV Dz, diabetes, CKD, peripheral arthritis.… https://t.co/0j1fH7OymW https://t.co/gqa1csylsn
Dr. John Cush @RheumNow( View Tweet )
Korean population-based study shows that from 2010 to 2023 prevalence of ank Spondylitis (AS) increased 27 per 100,000 (2010) to 82 per 100,000 (2023). Also increasing were # of pts >50 yrs (20-33%), #females (18-24%), Comorbidities, TNFi use (30-43%), while csDMARDs declined.… https://t.co/9NjU1IugaF https://t.co/kTCtIj2BjD
Dr. John Cush @RheumNow( View Tweet )
A substantial # of pts with inflammatory arthritis (IA) are not receiving adequate treatment for depression and anxiety(same as those IA-free controls). Canadian study of 6,951 w/ IA & depression, on 50% recv treatment & 20% psych. Rx for depression. Similar for 3,701 w/ IA &… https://t.co/CfpwEtLH3c

Dr. John Cush @RheumNow( View Tweet )

Just published, a new review of Axial spondyloarthritis from Baraliakos, et al in Lancet! https://t.co/0pIFM1Q2jO https://t.co/iGQ3ES7Nie
Dr. John Cush @RheumNow( View Tweet )
QD Clinic - Acute Neck & Back Pain Acute onset febrile, polyarthritis, neck and low back pain Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/2GqyqXAjbF https://t.co/vIeqdHyayV
Dr. John Cush @RheumNow( View Tweet )
Just published, a new review of Axial spondyloarthritis from Baraliakos, et al in Lancet! https://t.co/AuMTLo8iQO https://t.co/1icGoXKfB9
Dr. John Cush @RheumNow( View Tweet )
Surveys of US IBD specialty clinic pts (n=699) used SpA screening tools ( DETAIL & IBIS-Q) finding that 27% & 40%, respectively, screened positive, mostly for axial Sxs. In screen pos pts, 31% had a prior Rheum Dx or saw a rheumatologist in the year. https://t.co/1qlAl5xVfV https://t.co/HEwdLpgx2R
Dr. John Cush @RheumNow( View Tweet )

ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".

Read Article
Cycling vs Switching after TNFi Failure in axSpA https://t.co/XG16tgcLbr https://t.co/ifgMtAB7LF
Dr. John Cush @RheumNow( View Tweet )

Best of 2024: ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis

Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.

Read Article
95 IBD pts had Magnetic resonance enterography (MRE). While 6/95 (6.3%) developed IBD-arthritis (mean 11 mos), finding Sacroiliitison MRE did not increase this risk. IBD arthritis risk was linked to arthralgia (OR 84) & extraintestinal manifestations (OR 7.4)… https://t.co/NGWGKn75jG https://t.co/IqY6XHWqqy
Dr. John Cush @RheumNow( View Tweet )

Bah Humbug Vitamin D (12.20.2024)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Rheumatic findings in sarcoidosis are found in 10–40% of pts and include bone lesions, acute arthritis, chronic arthritis, axial disease, dactylitis, and sarcoid myopathy, https://t.co/WsfmKUS2n5 https://t.co/3j8OHgw7AS
Dr. John Cush @RheumNow( View Tweet )

Abuse of the Safety-Net 340B Drug Programs

Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing

Read Article

Biosimilars Do Impact Biologic Drug Costs

MedPage Today

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.

Read Article
International Map of Axial SpA study surveyed 5557 axSpA pts (3231 Europe, 770 USA); mean 44 yrs old; 55% females. mean BASDAI was 5.4 (75% had active disease -BASDAI ≥4). Active Dz highest in S. Africa 87%, vs 68% in Asia. Active Dz assoc w/ active functional limitation,… https://t.co/j8CjuLHHjD https://t.co/tV9S3b7YCM
Dr. John Cush @RheumNow( View Tweet )
JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar - Dx often delayed 6-8 yrs - Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/UbqVOr2iDx https://t.co/Ye5mYcbYX2
Dr. John Cush @RheumNow( View Tweet )

Don’t Buy Guitars (12.6.2024)

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article

Infertility linked to post-childbrith onset of systemic autoimmune disease

EurekAlert!

Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a naturally conceived birth compared to women without fertility problems.

Read Article

ICYMI: Reproductive Issues in axSpA: Fertility and Pregnancy

Axial spondyloarthritis (axSpA) affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their reproductive age. Two interesting abstracts about

Read Article
ACR24 SpA Panel: Key Discussions on Spondyloarthritis Join panelists Dr. Sheila Reyes, Dr. Adela Castro, Dr. Lihi Eder and Dr. Marina Magrey as they discuss key highlights and takeaways on spondyloarthritis sessions and abstracts presented at the 2024 ACR meeting in Washington,… https://t.co/XGcR6WDBFO https://t.co/0mJ08nheJJ
Dr. John Cush @RheumNow( View Tweet )

ACR24: Rheumatology Roundup

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Read Article
Assessment of axSpA Dr. Antoni Chan reviews abstracts 0818 and 0819, presented at #ACR24. https://t.co/2qI6DnnflP https://t.co/BuTdnlMfxq
Dr. John Cush @RheumNow( View Tweet )
Predicting flares in rheumatic diseases with machine learning Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.… https://t.co/6oFRp0zyBw https://t.co/fcMrJOg4mM
Dr. John Cush @RheumNow( View Tweet )
×